Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,703.20
    +1,322.80 (+2.63%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

The global stem cell therapy market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5%

ReportLinker
·4-min read

during the forecast period. Growth in this market is majorly driven by the increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants. However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.

New York, May 06, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Stem Cell Therapy Market by Type, Therapeutic Application, Cell Source - Global Forecasts to 2026" - https://www.reportlinker.com/p04759526/?utm_source=GNW


The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, bytype, during the forecast period
The stem cell therapy market is segmented intoallogeneic and autologous stem cell therapy.Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market.

The large share of this segment can be attributed to the lesser complexities involved in manufacturing Alaogeneic-based therapies. This segment is also expected to grow at the highest growth rate due to the increasing number of clinical trials in manufacturing allogeneic-based products.

Bone Marrow-derived MSCssegment accounted for the highest CAGR

Based on the cell source from which stem cells are obtained, the global stem cell therapy market is
segmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which include human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines). The bone marrow-derived MSCs segment is expected to witness the highest growth rate during the forecast period, owing to an increasing number of clinical trials focused on bone marrow-derived cell therapies and the rising demand for these cells in blood-related disorders.

Asia Pacific: The fastest-growing countryin thestem cell therapy market
Thestem cell therapy market is segmented into North America, Europe, Asia Pacific,RoW.The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period.

Factors such as the growing adoption of stem cell-based treatment in the region and the growing approval & commercialization of stem cell-based products for degenerative disorders drive the growth of the stem cell therapy market in the region.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80%and Demand Side 20%
• By Designation: C-level - 25%, D-level - 20%, and Others - 55%
• By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:
• Smith & Nephew (UK)
• MEDIPOST (South Korea)
• Anterogen (South Korea)
• CORESTEM (South Korea)
• PHARMICELL (South Korea)
• NuVasive (US)
• RTI Surgical (US)
• AlloSource (US)
• JCR Pharmaceuticals (Japan)
• Takeda Pharmaceutical Company (Japan)
• HolostemTerapieAvanzateS.r.l (Italy)
• Orthofix (US)
• Regrow Biosciences (India)
• Stempeutics Research (India)
• Athersys (US),
• Mesoblast (Australia),
• BioRestorative Therapies (US)
• Pluristem Therapeutics (Israel)
• BrainStorm Cell Therapeutics (US)
• ViaCyte (US)
• Kangstem Biotech (South Korea)
• Hope Biosciences (US)
• Cellular Biomedicine Group (US)
• and Personalized Stem Cells (US)

Research Coverage:
This report provides a detailed picture of thestem cell therapy market.It aims at estimating the size and future growth potential of the market across different segments, such as the service, end user, and region.

The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
Read the full report: https://www.reportlinker.com/p04759526/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001